Teva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral
August 4, 2017 6:01 AM EDTCredit Suisse downgraded Teva Pharma (NYSE: TEVA) from Outperform to Neutral with a price target of $25.00 (from $39.00).
Analyst Vamil Divan said as they look ahead they believe there are still no signs of stabilization for some of the key issues impacting TEVAs core... More
Teva Pharma (TEVA) Cracks Fresh Low, Now Down 19.65%
August 3, 2017 11:17 AM EDTTeva Pharma (NYSE: TEVA) Cracks Fresh Low, Now Down 19.65%
... MoreTeva Pharma (TEVA) Sinks 16% on Weak Results, Outlook
August 3, 2017 8:18 AM EDTTeva Pharma (NYSE: TEVA) shares sink nearly 16% in pre-open trade following weak results and outlook.
... MoreTeva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts Dividend
August 3, 2017 6:33 AM EDT(Updated - August 3, 2017 6:40 AM EDT)
Teva Pharma (NYSE: TEVA) reported Q2 EPS of $1.02, $0.04 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.76 billion.
GUIDANCE:
Teva Pharma sees Q3 2017 EPS of $4.30-$4.50, versus the consensus of $4.74.
We... More